INPPL1 and breast carcinoma: Indeed, it has been previously shown that this antibody specifically labels SHIP2 in MCF-7 breast cancer cells but not in the cells deficient for INPPL1 by CRISPR/Cas9 technology [75] and thus was considered as specific for immunostaining.